Sugi Predict

Sugi Predict / Compounds / SCHEMBL860462

SCHEMBL860462

SCHEMBL860462

CC(C)(C)[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](n2ccc(=O)[nH]c2=O)[C@]1(C)F

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ DUT P33316 3/20 0.45
▸ SLC29A1 Q99808 2/20 0.44
▸ SLC28A1 O00337 1/20 0.44
▸ SLC28A2 O43868 1/20 0.44
▸ SLC28A3 Q9HAS3 1/20 0.44
▸ P2RY2 P41231 1/20 0.42
▸ P2RY4 P51582 1/20 0.42
▸ POLA1 P09884 1/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ PDE4D Q08499 1/20 0.36
▸ PDE3A Q14432 1/20 0.36
▸ P2RY14 Q15391 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL860463 1.00 DUT (0.45) DUTSLC29A1SLC28A1SLC28A2SLC28A3
SCHEMBL20053425 1.00 DUT (0.45) DUTSLC29A1SLC28A1SLC28A2SLC28A3
SCHEMBL18672024 0.91 DUT (0.46) DUTSLC29A1SLC28A1SLC28A2SLC28A3
SCHEMBL21063983 0.91 DUT (0.46) DUTSLC29A1SLC28A1SLC28A2SLC28A3
SCHEMBL17560698 0.89 DUT (0.54) DUTSLC29A1SLC28A1SLC28A2SLC28A3
SCHEMBL21418793 0.89 DUT (0.54) DUTSLC29A1SLC28A1SLC28A2SLC28A3
SCHEMBL21755901 0.89 DUT (0.47) DUTSLC29A1SLC28A1SLC28A2SLC28A3
SCHEMBL12701381 0.86 DUT (0.45) DUTSLC29A1SLC28A1SLC28A2SLC28A3
SCHEMBL18269224 0.85 SLC28A1 (0.49) SLC29A1SLC28A1SLC28A2SLC28A3P2RY2
SCHEMBL29414441 0.85 SLC28A1 (0.46) DUTSLC29A1SLC28A1SLC28A2SLC28A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122038397-A Chemically modified siRNA molecule and application thereof 北京炫景瑞医药科技有限公司 2026-05-15 — — CN disclosed
US-20250057867-A1 NUCLEOSIDE PHOSPHORAMIDATES GILEAD SCIENCES INC (US) 2025-02-20 — — US disclosed
EP-3321275-B1 CRYSTALLINE FORM OF SOFOSBUVIR GILEAD SCIENCES INC (US) 2022-07-13 — — EP disclosed
EP-3290428-B1 TABLET COMPRISING CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1 (2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE GILEAD PHARMASSET LLC (US) 2021-10-13 — — EP disclosed
US-11008361-B2 Liver-specific delivery-based anti-hepatitis C prodrug nucleoside cyclo-phosphate compound and uses thereof ZHEJIANG PALO ALTO PHARMACEUTICALS, INC. (CN) 2021-05-18 — — US disclosed
CN-105085592-B N- [ (2' R) -2' -deoxy-2 ' -fluoro-2 ' -methyl-P-phenyl-5 ' -uridylyl ] -L-alanine 1-methylethyl ester and process for preparing same 吉利德制药有限责任公司 2021-04-27 — — CN disclosed
EP-3613753-A1 LIVER-SPECIFIC DELIVERY-BASED ANTI-HEPATITIS C PRECURSOR DRUG NUCLEOSIDE CYCLOPHOSPHATE COMPOUND AND USE Zhejiang Palo Alto Pharmaceuticals, Inc (CN) 2020-02-26 — — EP disclosed
US-20200048299-A1 LIVER-SPECIFIC DELIVERY-BASED ANTI-HEPATITIS C PRODRUG NUCLEOSIDE CYCLO-PHOSPHATE COMPOUND AND USES THEREOF ZHEJIANG PALO ALTO PHARMACEUTICALS,INC (CN) 2020-02-13 — — US disclosed
EP-3321275-A1 CRYSTALLINE FORM OF SOFOSBUVIR Gilead Pharmasset LLC (US) 2018-05-16 — — EP disclosed
EP-3290428-A1 TABLET COMPRISING CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1 (2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE Gilead Pharmasset LLC (US) 2018-03-07 — — EP disclosed
US-20130165644-A1 NUCLEOSIDE PHOSPHORAMIDATES GILEAD PHARMASSET LLC (US) 2013-06-27 — — US disclosed
US-20130137654-A1 NUCLEOSIDE PHOSPHORAMIDATES GILEAD PHARMASSET LLC (US) 2013-05-30 — — US disclosed
US-20130137654-A1 NUCLEOSIDE PHOSPHORAMIDATES GILEAD PHARMASSET LLC (US) 2013-05-30 — — US disclosed
EP-2552930-A2 NUCLEOSIDE PHOSPHORAMIDATES Gilead Pharmasset LLC (US) 2013-02-06 — — EP disclosed
EP-2432792-A1 N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL]-L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION Pharmasset, Inc. (US) 2012-03-28 — — EP disclosed
US-20110251152-A1 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2011-10-13 — — US disclosed
WO-2011123645-A2 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2011-10-06 — — WO disclosed
WO-2010135569-A1 N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL] -L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION PHARMASSET, INC. (US) 2010-11-25 — — WO disclosed
US-20100298257-A1 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2010-11-25 — — US disclosed
US-20100298257-A1 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2010-11-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165644-A1 NUCLEOSIDE PHOSPHORAMIDATES PNP, RNGTT, NSUN2 DUT 10/4885SLC29A1 40/4885SLC28A1 67/4885
US-20200048299-A1 LIVER-SPECIFIC DELIVERY-BASED ANTI-HEPATITIS C PRODRUG NUCLEOSIDE CYCLO-PHOSPHATE COMPOUND AND USES THEREOF SLC6A7, DCTPP1, PYGL DUT 436/4885SLC29A1 16/4885SLC28A1 65/4885
US-11008361-B2 Liver-specific delivery-based anti-hepatitis C prodrug nucleoside cyclo-phosphate compound and uses thereof SLC6A7, DCTPP1, PYGL DUT 436/4885SLC29A1 16/4885SLC28A1 65/4885
US-20250057867-A1 NUCLEOSIDE PHOSPHORAMIDATES PNP, RNGTT, NSUN2 DUT 13/4885SLC29A1 36/4885SLC28A1 59/4885
US-20130137654-A1 NUCLEOSIDE PHOSPHORAMIDATES PNP, RNGTT, NSUN2 DUT 10/4885SLC29A1 40/4885SLC28A1 67/4885
US-20100298257-A1 NUCLEOSIDE PHOSPHORAMIDATES PNP, RNGTT, NSUN2 DUT 10/4885SLC29A1 40/4885SLC28A1 67/4885
US-20110251152-A1 NUCLEOSIDE PHOSPHORAMIDATES PNP, RNGTT, NSUN2 DUT 13/4885SLC29A1 36/4885SLC28A1 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.